Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
Alteogen Inc
Alvotech SA
Amgen Inc
Celltrion Inc
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cingen Co
Formycon AG
GlycoNex Inc
Hexal AG
Huons Global Co Ltd
i2 Pharmaceuticals Inc
Johnson & Johnson
Kidswell Bio Corp
Luye Pharma Group Ltd
Mabwell Shanghai Bioscience Co Ltd
Neuracle Genetics Inc
Ocular Therapeutix Inc
Oncosimis Biotech Pvt Ltd
Oxurion NV
Panolos Bioscience
PharmAbcine Inc
Prestige BioPharma Ltd
Regeneron Pharmaceuticals Inc
Rophibio Inc
Sam Chun Dang Pharm Co Ltd
Samsung Bioepis Co Ltd
Shilpa Medicare Ltd
Synermore Biologics Co Ltd
Zeen Biotechnology Co Ltd
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
conbercept - Drug Profile
Product Description
Mechanism Of Action
History of Events
KH-906 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NG-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PB-101 - Drug Profile
Product Description
Mechanism Of Action
SL-186 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SL-188 - Drug Profile
Product Description
Mechanism Of Action
History of Events
THR-317 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ziv-aflibercept - Drug Profile
Product Description
Mechanism Of Action
History of Events
ziv-aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
Featured News & Press Releases
Jul 14, 2022: New antibody therapy shows promising results for advanced, treatment-refractory pediatric brain cancer
Jul 07, 2022: Alvotech initiates patient study for AVT06, a proposed biosimilar for Eylea
Jun 29, 2022: EYLEA (aflibercept) injection sBLA for Every 16-week dosing regimen in patients with diabetic retinopathy accepted for FDA review
Apr 25, 2022: Shilpa Medicare receives NoC from RCGM, Dept. of Biotechnology for its Biosimilar Aflibercept
Feb 22, 2022: Bayer Gets Eylea Biosame approval in Japan as it braces for biosimilar debuts
Feb 11, 2022: Regeneron presents encouraging phase 2 results for high-dose aflibercept 8 mg in wet age-related macular degeneration at Angiogenesis Meeting
Nov 10, 2021: Bayer submits Aflibercept for regulatory approval in the EU and Japan for retinopathy of prematurity in premature babies
Aug 25, 2021: Regeneron’s aflibercept meets primary goal in Phase II wet AMD trial
Jul 27, 2021: Huma Sues Regeneron Over Price Of Eylea Macular Degeneration Drug
May 04, 2021: Sandoz to study biosimilar aflibercept in Phase III AMD trial
Apr 12, 2021: Oncurious reports encouraging data from phase 1 dose escalation study of TB-403 in paediatric subjects with relapsed or refractory medulloblastoma presented at the American Association for Cancer Research 2021 Annual Meeting
Apr 09, 2021: Kanghong Pharmaceutical stops clinical study of ocular drug Conbercept
Apr 09, 2021: ONCURIOUS presenting clinical and preclinical data at upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting
Mar 31, 2021: Regeneron’s Eylea lowers vision-threatening events in diabetes trial
Mar 28, 2021: Kanghong pharmaceutical: khb-1802 clinical trial suspended in France
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022